CVS Health Corporation (NYSE:CVS) Position Increased by TD Private Client Wealth LLC

TD Private Client Wealth LLC increased its position in shares of CVS Health Corporation (NYSE:CVS) by 152.4% in the 1st quarter, Holdings Channel.com reports. The fund owned 78,914 shares of the pharmacy operator’s stock after buying an additional 47,649 shares during the quarter. TD Private Client Wealth LLC’s holdings in CVS Health were worth $5,346,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hopwood Financial Services Inc. bought a new position in CVS Health during the fourth quarter valued at about $29,000. McIlrath & Eck LLC raised its holdings in CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock valued at $32,000 after buying an additional 174 shares in the last quarter. Sierra Ocean LLC raised its holdings in CVS Health by 584.8% during the first quarter. Sierra Ocean LLC now owns 719 shares of the pharmacy operator’s stock valued at $49,000 after buying an additional 614 shares in the last quarter. MV Capital Management Inc. raised its holdings in CVS Health by 63.9% during the first quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator’s stock valued at $50,000 after buying an additional 289 shares in the last quarter. Finally, Dunhill Financial LLC raised its holdings in CVS Health by 147.2% during the first quarter. Dunhill Financial LLC now owns 749 shares of the pharmacy operator’s stock valued at $51,000 after buying an additional 446 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Guy P. Sansone acquired 1,570 shares of the firm’s stock in a transaction on Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the acquisition, the director owned 12,007 shares of the company’s stock, valued at $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.22% of the company’s stock.

CVS Health Stock Up 1.2%

CVS stock opened at $67.38 on Monday. The company has a market cap of $85.23 billion, a PE ratio of 16.08, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $72.51. The business’s 50-day simple moving average is $65.11 and its 200 day simple moving average is $61.71.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.31 earnings per share. On average, research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on CVS. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a research report on Tuesday, April 15th. Truist Financial raised their price target on CVS Health from $82.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, May 12th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $84.00 price target (up from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Finally, UBS Group raised their price target on CVS Health from $67.00 to $71.00 and gave the company a “neutral” rating in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.06.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.